Jones Trading upgrades Capricor stock rating ahead of FDA decision
Jones Trading upgraded Capricor Therapeutics (CAPR) to Buy with a $25 price target ahead of an FDA decision on deramiocel. The stock is down 72% over six months. The firm estimates a 35% chance of approval, which could lead to 2.5x upside. Capricor reported a larger-than-expected Q3 2026 loss of $0.73 per share but has sufficient cash reserves. The FDA decision is on November 22.
How this was made
The 30-second read
Why it matters
The upgrade adds a new catalyst to the stock, potentially shifting short‑term sentiment and volume.
Market read
Analyst upgrade ahead of a pivotal regulatory decision creates a short‑term trading opportunity for CAPR.
What to watch
The trial's secondary endpoint failure and advisory committee split may signal deeper concerns not captured by the upgrade.
Background
Capricor Therapeutics (CAPR) is a small‑cap biotech awaiting FDA decision on its lead therapy deramiocel. The company recently reported a Q3 loss and holds ample cash.
Ticker impact
Jones Trading upgraded Capricor Therapeutics to Buy with a $25 price target ahead of the FDA PDUFA decision on November 22.
likely upward pressure as traders price in the approval probability and target price.
The upgrade is a fresh, primary disclosure with a concrete target; the market will react to the regulatory catalyst.
Market effects
Biotech sector may see broader risk‑on sentiment ahead of multiple PDUFA dates.
U.S. biotech stocks could experience modest gains in early trade.
Limited to investors tracking FDA outcomes; no immediate global macro effect.
Counterpoint
If the FDA issues a complete response letter, the stock could drop sharply, making the upgrade premature.
Key entities
- analystJones Trading
Research firm that issued the upgrade and $25 price target.
- regulatorFDA
U.S. agency expected to render a decision on Capricor's PDUFA date.
